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Abstract  25 
Background: Recent reports suggest that prescriptions for thyroid 26 
hormones have increased. We therefore analyzed recent trends in and 27 
determinants of prevalence of treated hypothyroidism across the United 28 
Kingdom (UK). 29 
Methods: UK-wide data held by the National Health Service and the Office 30 
of National Statistics were examined. The main outcome measured was 31 
trends in prevalence of treated hypothyroidism between 2005 till 2014. In 32 
addition, linear trend forecasting was performed to estimate projected 33 
trends in prevalence of treated hypothyroidism up to the year 2025. 34 
Furthermore, determinants of variation of treated hypothyroidism 35 
prevalence across each of the 237 health areas in the UK in 2014 and its 36 
association with other health conditions were explored by multivariate 37 
linear regression analyses. 38 
Results: The prevalence of treated hypothyroidism increased from 2.3% 39 
(1.4 million) to 3.5% (2.2 million) of the total UK population between the 40 
years 2005 – 2014 and is projected to rise further to 4.2% (2.9 million) 41 
by 2025. There was large geographical variation of treated 42 
hypothyroidism across the UK with London having the lowest (1.4%) and 43 
the Western Isles of Scotland having the highest (6.3%) prevalence. This 44 
variation was attenuated, but did not completely disappear, after some 45 
potential determinants were accounted for. Prevalence of treated 46 
hypothyroidism was independently related to health areas with higher 47 
proportion of individuals who were female, White, obese, and negatively 48 
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associated with prevalent cigarette smoking. Prevalence of treated 49 
hypothyroidism was significantly associated with frequency of prevalent 50 
atrial fibrillation but not with other major health conditions including 51 
ischemic heart disease and osteoporosis. 52 
Conclusions: Between 2005 and 2014, prevalence of treated 53 
hypothyroidism increased across the UK, has wide geographical variation, 54 
and is likely to increase further for the foreseeable future. Clinical effects 55 
and cost-effectiveness of the trend in increasing treatment of 56 


















Primary hypothyroidism is a common endocrine condition characterized by 74 
raised serum thyrotropin (TSH) and reduced circulating thyroid hormone 75 
concentrations. Primary hypothyroidism is more common in females and 76 
peak incidence rates occur between 40-50 years of age with autoimmune 77 
thyroid disease as the most frequent etiology (1). Furthermore, over the 78 
last few decades there has been an increasing interest in subclinical 79 
hypothyroidism (SCH) – a milder condition characterized by a raised 80 
serum TSH and with thyroid hormones in the reference range. Current 81 
guidelines recommend treatment of SCH only in specific situations such as 82 
younger individuals with hypothyroid-symptoms (2) or pregnant women 83 
who are TPOAb (thyroid peroxidase antibody) positive (3). Data from 84 
small samples suggest that the prevalence of treated hypothyroidism 85 
(both overt and SCH) in the UK and the USA is approximately 3% (4 – 6). 86 
Levothyroxine (LT4), a synthetic isomer of the thyroid hormone thyroxine, 87 
is the recommended and ubiquitously used treatment in patients with 88 
hypothyroidism (7, 8). Poor control of treated hypothyroidism, as 89 
evidenced by abnormal serum TSH levels, is seen in 35 – 60% of patients 90 
(9, 10) and is associated with adverse bone and cardiac outcomes (11).  91 
Several recent reports have highlighted that prescribing of LT4 has 92 
increased both in the USA and the UK (12, 13). The reasons underlying 93 
these increases in LT4 prescribing are unclear. Previous reports suggest 94 
that increased propensity to treat older individuals, those with milder 95 
elevation in serum TSH and reduced length of LT4 prescriptions might be 96 
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factors associated with increased LT4 prescribing (9, 14, 15). However, 97 
contemporary data on the trends in the prevalence of treated 98 
hypothyroidism reflective of the overall population and current clinical 99 
practice are lacking. We, therefore, interrogated UK national databases to 100 
study recent trends in the prevalence of treated hypothyroidism and to 101 
evaluate population-based determinants between the various health-areas 102 
of the UK.  103 
 104 
Methods 105 
The aim of this analysis was to study trends in the overall prevalence of 106 
treated hypothyroidism in the UK between 2005 and 2014 and to quantify 107 
variations in prevalence of treated hypothyroidism at local health area 108 
population level. In addition, we sought to forecast prevalence of treated 109 
hypothyroidism for the future based on recent trends. To achieve this, 110 
UK-wide data held by the National Health Service (NHS) and the Office of 111 
National Statistics (ONS) was examined.   112 
Health areas in the United Kingdom: Information regarding prevalence of 113 
medical conditions and health-related parameters in the year 2014 was 114 
obtained from the health body for each geographical area in the UK 115 
(n=237). These local health bodies have different structures and 116 
responsibilities but collect the same information. These are the Clinical 117 
Commissioning Groups in England (n=211), Health Boards in Wales 118 
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(n=7), NHS boards in Scotland (n=14) and Health and Social Care Trusts 119 
in Northern Ireland (n=5).  120 
Quality Outcomes Framework database: The Quality and Outcomes 121 
Framework (QOF) is a major pay-for-performance program that was 122 
introduced into UK primary care in 2004 and accounts for approximately a 123 
quarter of general practice income (16). The QOF is intended to reward 124 
practices for the provision of 'quality care' and to reduce variation across 125 
the country. QOF points are achieved based on the proportions of patients 126 
on defined disease registers who receive defined interventions. Points are 127 
scored by maintaining a register and not by the number of patients in 128 
each register. Therefore, there is no incentive for initiating treatment or 129 
changing clinical practice. Participation by practices in the QOF is 130 
voluntary, though participation rates are very high; for example, in 2015, 131 
the QOF dataset includes data from nearly 99% of GP practices in England 132 
that were open and active at some point in the reporting period (17). 133 
Hypothyroidism was one of several clinical conditions that were covered 134 
by the QOF until 2015, when it was no longer included due to 135 
reorganization. Data for each individual component country of the UK was 136 
obtained separately from independent databases for that country for the 137 
period between 2005 and 2014 (the last year for when the data was 138 
available) (Online appendix).  A treated hypothyroidism case was defined 139 
by a LT4 prescription for any person of any age. Prevalence of treated 140 
hypothyroidism was calculated by dividing the number of patients with 141 
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hypothyroidism on the QOF register with the total number of patients 142 
registered with all of the participating practices in each health area across 143 
the UK.  144 
To assess variation in prevalence of hypothyroidism across the UK 145 
additional data on demographics (total population size, proportion aged 146 
more than 65 years, race and sex), mean index of multiple deprivation 147 
scores, percentage of tobacco smokers, percentage of population with 148 
obesity, and proportion of the population with concomitant potentially 149 
related medical conditions (ischemic heart disease, heart failure, atrial 150 
fibrillation, hypertension, stroke/transient ischemic attack, diabetes 151 
mellitus, depression, dementia, osteoporosis, and chronic kidney disease) 152 
were obtained for each health area from the QOF and/or the ONS 153 
database registrations in 2014. Details in Appendix Table 1 (online only).   154 
Statistics  155 
The overall prevalence of treated hypothyroidism across the UK between 156 
the years 2005 and 2014 was adjusted for median age of the population, 157 
percentage of women, percentage of smokers, percentage of White 158 
individuals, percentage of people who were obese, and year of evaluation.  159 
The association of demographic, social and lifestyle-related potential 160 
determinants (as independent covariates) with treated hypothyroidism 161 
prevalence in the year 2014 (as the dependent variable) was analyzed 162 
using multiple linear regression models. First, univariate regression 163 
models were fitted to identify relevant determinants (percentages of age 164 
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> 65 years, females, white people, obese individuals, smokers and index 165 
of multiple deprivation score) and final models were built using a stepwise 166 
approach. For the stepwise approach, we entered variables into the model 167 
based on their biological relevance (i.e. adjust outcome analyses for 168 
potential demographic confounders) and also, we adjusted these further 169 
to identify whether the association of hypothyroidism prevalence with 170 
diseases linked to each other (i.e. atrial fibrillation and stroke) could be 171 
mediated due to that link. We built these models in a stepwise manner 172 
that was not automated – i.e. we did not use p values or other criteria to 173 
enter/remove variables. We used a stepwise model building approach to 174 
assess any large changes after the inclusion of variables to identify 175 
potential model problems. Non-linearity was assessed by adding quadratic 176 
terms with subsequent visual inspection of regression plots and 177 
assessment of changes in the effect estimates and/or explained variance 178 
of the model (relevant non-linear effects were identified for percentage 179 
aged >65 years, females and white population). Variables that were 180 
associated with treated hypothyroidism prevalence in univariate analyses 181 
were then combined into a multivariate analysis. Adjusted R-squared 182 
values were used to examine degree of variation in hypothyroidism 183 
prevalence that is explained by the model.  184 
In addition, to assess the association of prevalence of treated 185 
hypothyroidism with other major health conditions, similar multivariate 186 
models were created with prevalence of these diseases as dependent 187 
variables and associated demographic, social, lifestyle-related, and 188 
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prevalence of treated hypothyroidism as independent variables were 189 
combined in multivariate regression analyses. Furthermore, for each 190 
individual dependent variable other health conditions that could be 191 
causally linked were added to the final model. For example, prevalence of 192 
atrial fibrillation was added to the model assessing the association 193 
between stroke disease and hypothyroidism, and so on. Moreover, due to 194 
the number of diseases being evaluated (n=10), a p value of less than 195 
0.005 was used to denote significance for this particular analysis.  We 196 
calculated the variance inflation factor (VIF) to assess collinearity. To fulfil 197 
model assumptions, variables that had a high VIF (>2.5) were centered 198 
and standardized (18). Assumption of normal distribution of residuals of 199 
the model were assessed and confirmed by visual inspection of 200 
standardized residuals and Q-Q plots.  201 
Linear trend forecasting was performed to estimate the projected 202 
estimate of the prevalence of treated hypothyroidism in the UK taking into 203 
account previous trends and the predicted changes in total population. 204 
Observed and fitted values were calculated using ARIMA (autoregressive 205 
integrated moving average) modelling adjusted for the projected total UK 206 
population until 2025. These population projections take into account 207 
population demographic change estimates (migration, deaths, births and 208 
longevity) (19). From these forecasting models a stationary R-squared 209 
value (a measure that compares the stationary part of the model to a 210 
simple mean model, is preferable to ordinary r2 when there is a trend or 211 
seasonal pattern and can range from negative infinity to 1) was 212 
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calculated. The statistical software Minitab version 17.0 and SPSS version 213 
22.0 (SPSS Inc., Chic, Ill, USA) were utilized for all analyses. Geo-214 
mapping was undertaken using Tableau version 10.3. 215 
 216 
Results 217 
Trends in Prevalence of treated hypothyroidism, 2005 - 2014  218 
Overall, in the UK, the crude prevalence of treated hypothyroidism has 219 
increased by 57%: from 1.43 million (2.3%) to 2.24 million (3.5%) 220 
between 2005 and 2014. All the constituent countries in the UK have seen 221 
an increase in the prevalence of treated hypothyroidism over this period. 222 
However, there are consistent differences in prevalence between the 223 
constituent countries with England having the lowest and Scotland and 224 
Wales having the highest prevalence (Figure 1). Adjustment for potential 225 
confounders made a slight difference to these results. For example, 226 
adjusted prevalence rates for treated hypothyroidism for the UK were 227 
2.4% for 2005 and 3.4% for 2014. The adjusted year-on-year increase in 228 
the prevalence of treated hypothyroidism between 2005 and 2014 was 229 
significant (p=0.03).  230 
 231 
Variation in prevalence of treated Hypothyroidism across the UK in 232 
2014  233 
Data was available from all 237 health areas of the UK comprising 9711 234 
participating General Practices. The smallest area by population was 235 
Orkney (population of 20,803) whereas the largest was Greater Glasgow 236 
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and Clyde (population of 1,316,735). There were striking differences in 237 
the prevalence of treated hypothyroidism across the various geographical 238 
areas of the UK, with the lowest prevalence in the Central London area 239 
(1.4%) and the highest in the Western Isles of Scotland (6.3%). (Figure 240 
2A).   241 
 242 
Determinants of prevalence of treated hypothyroidism across 243 
health areas 244 
In univariate analysis, a number of variables were associated with the 245 
prevalence of treated hypothyroidism in each health area in the UK (Table 246 
2, Appendix). In the multivariate analysis, prevalence of treated 247 
hypothyroidism was positively associated with the population health area 248 
percentage of females, percentage of White individuals, percentage 249 
prevalence of obesity, and negatively associated with percentage of 250 
smokers (Supplementary Table 3) (Figure 3). The proportion of 251 
individuals aged more than 65 years and the index of multiple deprivation 252 
score of each health area were no longer significantly related to 253 
prevalence of treated hypothyroidism after multivariate adjustment. The 254 
final model explained 52% of the variation in prevalence of treated 255 
hypothyroidism between the different health areas.  256 
Once the significant determinants of treated hypothyroidism were 257 
adjusted for, the variation in treated hypothyroidism across the UK were 258 
attenuated (Figure 2B). For example, the adjusted prevalence of treated 259 
hypothyroidism in Central London was higher (2.6%) and was lower in the 260 
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Western Isles of Scotland (4.1%).  261 
Associations of treated hypothyroidism with major health 262 
conditions across health areas 263 
The prevalence of treated hypothyroidism in each health area was 264 
significantly associated with the prevalence of atrial fibrillation ( co-265 
efficient 0.20, 95% confidence intervals 0.14 – 0.26, p< 0.001); this 266 
association attenuated after further addition of prevalent ischemic heart 267 
disease ( co-efficient 0.10, 95% confidence intervals 0.04 – 0.15, p< 268 
0.001) (Figure 4). All other major health conditions evaluated however 269 
showed no significant association with prevalent hypothyroidism. 270 
Specifically, there was no statistically significant association between 271 
prevalence of ischemic heart disease, heart failure or osteoporosis with 272 
the prevalence of treated hypothyroidism across each of the health areas 273 
studied. The only exception was for the prevalence of hypertension, which 274 
remained significantly associated with prevalence of treated 275 
hypothyroidism even after additional adjustment for multiple analyses. 276 
However, the VIF was high suggesting high level of multicollinearity. This 277 
association therefore needs to be interpreted with caution (Table 4 in 278 
Appendix).  279 
 280 
Projected trends in prevalence of treated hypothyroidism between 281 
2015 and 2025 282 
Forecasting trend modelling (stationary R-squared=0.965) suggests that 283 
the prevalence of treated hypothyroidism will increase further to 4.65% 284 
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(95% CI 4.47 – 4.83) of the total population in the year 2025, considering 285 
UK population projected changes and if there is no alteration to current 286 
prescribing habits (figure 5). In 2025, the population of the UK is 287 
estimated to be just over 69 million and based on these models the 288 
number of people with treated hypothyroidism is therefore projected at 289 
3.23 (95% CI 3.10 – 3.35) million.  290 
 291 
Discussion 292 
The prevalence of treated hypothyroidism has increased in the UK in the 293 
last ten years (between 2005 and 2014) from 2.3 to 3.5%, thereby 294 
affecting 0.8 million more individuals. The reasons behind this increase 295 
are unclear but likely to be multifactorial and include a growing population 296 
with changes in demographic features and lifestyle. The results of our 297 
analysis do not provide any data on whether there is an increase in the 298 
incidence of hypothyroidism or if there is an increased propensity to 299 
detect and treat milder (subclinical) forms of the condition. There is wide 300 
geographic variation within the UK in the prevalence of treated 301 
hypothyroidism, which is partly explained by population demographics 302 
and lifestyle habits in that area such as proportion of women, white 303 
population, obesity levels and smoking habits. In 2014, two and a quarter 304 
million individuals were being treated for hypothyroidism in the UK. If the 305 
current trend continues then it is likely that the prevalence of treated 306 
hypothyroidism will rise further to 4.65% of the total population (affecting 307 
just over 3.2 million individuals). 308 
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There is limited data available on trends in the prevalence of treated 309 
hypothyroidism at a national level. Analysis from several NHANES cycles 310 
in US adults (aged 20 years or older) showed that prevalence of thyroid 311 
hormone use increased from 5.1% in 1999-2000 to 6.4% in 2011-12 312 
(p=0.007 for trend) (5). There were increases observed in both men and 313 
women (from 2 to 3.2% and 8 to 9.3%, respectively) as well as in 314 
younger (40 – 64-year olds: 5.9 to 6.9% and >65-year olds: 13 to 15%) 315 
over this time-period. However, this data was obtained from a relatively 316 
small group (approximately 5000 participants per each NHANES cycle), 317 
although data were weighted to be nationally representative. 318 
Interestingly, the biggest increase in thyroid hormone use was seen in 319 
non-Hispanic Whites. An interrogation of a large population-based health 320 
database in Tayside, Scotland found that the prevalence of treated 321 
hypothyroidism increased in both men and women, from 0.5 to 0.9% and 322 
3.1 to 5.1%, respectively, between 1994 to 2001, which was attributed to 323 
increasing incidence and earlier diagnosis and treatment (20). Analysis of 324 
community prescription data from England showed that the number of 325 
prescriptions for thyroid hormones and the ingredient costs increased 326 
between 1998 and 2007 whilst the average length of prescriptions 327 
reduced (15). The data provided in the current analysis not only confirms 328 
these earlier results but also provides a more accurate and contemporary 329 
representation of treated hypothyroidism prevalence and variation across 330 
the entire population of the UK. Furthermore, as treated hypothyroidism is 331 
no longer on the QOF list of conditions for which data is gathered, it is 332 
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unlikely that updates for the results of this analysis will be possible in the 333 
future using similar methodology.    334 
There are several possible explanations for the increased trend observed 335 
in the prevalence of treated hypothyroidism. The total population of the 336 
UK has increased from 60.4 million to 64.6 million (an increase of 6.9%) 337 
between 2005 and 2014 (21); partly due to the increase in longevity 338 
(average lifespan has increased from 79.1 to 81.1 years between 2005 339 
and 2015 - an increase of 2.5%) (22). These small increases however do 340 
not fully explain the large relative increase in the prevalence of treated 341 
hypothyroidism. Other possible reasons could be an increase in TFT 342 
checking leading to higher case-finding and treatment (23), increased 343 
propensity to treat milder forms of hypothyroidism particularly in older 344 
individuals (9), and a decline in cigarette smoking (24) leading to a rise in 345 
TSH and TPOAb levels (25). A raised serum TSH – a diagnostic hallmark 346 
of hypothyroidism – is influenced by increases with age but age-specific 347 
reference ranges are not utilized (26, 27). Our analysis however does not 348 
confirm that areas with higher proportion of older individuals (>65 years) 349 
have greater prevalence of treated hypothyroidism once other factors are 350 
taken into account. At the start of the time-period corresponding to the 351 
analysis reported here, some experts believed that the upper limit of the 352 
TSH reference range should be reduced - which could have influenced 353 
some clinicians to prescribe treatments at lower TSH levels (28). Other 354 
possible explanations for the increase in the prevalence of treated 355 
hypothyroidism could be due to the increasing use of ablative radioiodine 356 
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and surgical therapies for both benign and cancerous thyroid diseases 357 
(29, 30) as well as increasing use of thyroid hormones during pregnancy 358 
(31). Finally, increase in body mass index leads to an increase in serum 359 
TSH levels (32) and our analysis suggests that areas with higher 360 
prevalence of obesity are associated with higher prevalence of treated 361 
hypothyroidism. 362 
     363 
The results of our analysis have several implications. It is increasingly 364 
becoming apparent that a mildly raised serum TSH (subclinical 365 
hypothyroidism) is not associated with adverse outcomes, particularly in 366 
older individuals (33 – 35). Importantly, short-term trials of treatment of 367 
subclinical hypothyroidism in older individuals have not shown any 368 
improvement in symptoms or quality of life (36, 37). In addition, several 369 
observational studies in older individuals have shown that higher serum 370 
thyroxine levels and/or lower circulating TSH concentrations are 371 
associated with worse outcomes (38 – 40). There are economic 372 
implications of increased LT4 prescribing as well with sparse evidence of 373 
cost-effectiveness particularly in the elderly. In the UK, a diagnosis of 374 
hypothyroidism leads to exemption from payment of prescription charges 375 
(that is, free medications) in people who would otherwise have to pay 376 
(41). Poor control of hypothyroidism whilst on treatment, as evidenced by 377 
abnormal serum TSH levels, is common (9, 10) and has been associated 378 
with increased risk of cardiovascular disease, atrial fibrillation and 379 
osteoporotic fractures (11). It is concerning that our data suggests that 380 
 17 
areas with higher prevalence of treated hypothyroidism have a higher 381 
frequency of atrial fibrillation, independent of other risk factors. However, 382 
it is unclear from our data whether there is a causal link between the two 383 
conditions and whether this is related to poor control (abnormal TSH 384 
levels).  It is likely that a significant proportion of older community-385 
dwelling treated hypothyroid patients have iatrogenic thyrotoxicosis and 386 
therefore are at risk of developing atrial fibrillation (42). Reassuringly, the 387 
current analysis does not suggest that areas with higher prevalence of 388 
treated hypothyroidism are associated with higher occurrence of other 389 
major diseases such as ischemic heart disease, heart failure, 390 
osteoporosis, depression or dementia.  391 
Our data has several strengths. This is the first report, as far as we are 392 
aware, outlining the prevalence of treated hypothyroidism using a 393 
national-level database. The data obtained from the QOF has been shown 394 
to be reliable and accurate in other conditions (43). In addition, we were 395 
able to analyze geographical variation across the entire country and study 396 
population-level factors that may be associated with the variation in 397 
prevalence. Another strength of our data is that it reflects contemporary 398 
clinical practice. We were not able to assess if the management of 399 
hypothyroidism was ‘appropriate’ or following guidelines. However, it does 400 
confirm, not surprisingly, that clinicians vary in how they manage primary 401 
hypothyroidism (9). This analysis has some weaknesses too. The results 402 
obtained may not be generalized to other countries as the health care 403 
model and data collection methodology may be different. In addition, data 404 
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was collected at the population level and therefore several important 405 
individual-level or sub-group-level factors such as demographic details 406 
(age, sex and smoking status), underlying etiology of hypothyroidism, 407 
serum TSH and thyroid hormone level at diagnosis, control of 408 
hypothyroidism based on serum TSH levels on treatment, and symptoms 409 
and quality of life could not be assessed – thus leading to potential 410 
ecological inference fallacy. In addition, this data is unable to inform us if 411 
the treatment of hypothyroidism was ‘appropriate’ or not. There is 412 
evidence to suggest that approximately 6% of individuals are commenced 413 
on treatment with thyroid hormones when they are euthyroid (9) although 414 
there is also evidence that this is not associated with any benefit and 415 
could potentially cause harm (44). Furthermore, iodine status of each 416 
health area and effect of endocrine disruptors on the prevalence of 417 
treated hypothyroidism could not be assessed (45, 46). The prevalence of 418 
some determinant factors (such as smoking and obesity), associated 419 
chronic major health conditions (such as diabetes mellitus, depression and 420 
chronic kidney disease) were not available for children (<15 – 18 years, 421 
depending on condition), or in younger individuals (< 50 years for 422 
osteoporosis). This may have led to some error in our results although the 423 
number of individuals that may have been excluded is likely to be very 424 
small. Finally, our projections for the future are based on previous years’ 425 
data on prevalence and changes in population numbers and/or 426 
demographics as well as clinical practice (including TSH thresholds for 427 
considering treatment) may affect actual observations.  428 
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In conclusion, this analysis demonstrates that the diagnosis of treated 429 
hypothyroidism has increased in the UK between 2005 and 2014. There is 430 
wide geographical variation in the prevalence of the condition, partly 431 
related to population demographics in each area and, therefore, could 432 
change as a result of demographic or lifestyle changes. There appears to 433 
be an association between the prevalence of treated hypothyroidism and 434 
atrial fibrillation that requires further evaluation. The use of age- and 435 
race/ethnicity-appropriate reference ranges for TSH need to be 436 
considered. In addition, the clinical outcomes and cost-effectiveness of 437 
increased treatment of hypothyroidism across various age and 438 
racial/ethnic groups – mostly for marginally elevated serum TSH levels – 439 
needs to be studied in a prospective manner.  440 
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